Dengue virus is a member of the flavivirus family, which includes Zika virus, West Nile virus and Japanese Encephalitis virus. Many of the proteins expressed by these viruses are very similar, and serological testing for these viruses can be complicated by problems of cross-reactivity. In this context, the use of highly purified antigens, that are glycosylated and folded as native proteins can be highly important in the development of accurate immunoassays. With more than one-third of the world’s population living in areas at risk of transmission, dengue infection is a leading cause of illness and death in the tropics and subtropics (ref WHO for Guidelines for Diagnosis, Treatment, Prevention & Control, 2009). Dengue is caused by any one of four related viruses (DENV1-4) which are transmitted by mosquitoes and responsible for infecting as many as 390 million people yearly (Bhatt , et al., 2013). It is a febrile illness that affects infants, young children and adults with symptoms appearing 3-14 days after the infective bite. Symptoms range from mild fever, to incapacitating high fever, with severe headache, pain behind the eyes, muscle and joint pain, and rash. There is no vaccine or any specific medicine to treat dengue. Severe dengue (also known as dengue hemorrhagic fever) is characterized by fever, abdominal pain, persistent vomiting, bleeding and breathing difficulty and is a potentially lethal complication, affecting mainly children. Early clinical diagnosis and careful clinical management by trained physicians and nurses increase survival of patient. More recently there has been increased interest in the potential of antibody-based immunotherapy as treatment for dengue. The dengue envelope (E) protein is arranged as antiparallel homodimers on the surface of the mature virion, comprising a total of 180 E proteins on the virion surface (Zhang, et al., 2013). It is composed of three domains, DI-DIII, in which DII contains the fusion loop required for viral entry (Modis, et al., 2004). An engineered cross-neutralizing humanized antibody targeting the DENV E domain III has been demonstrated to neutralize DENV in mice, at clinically relevant viral loads or in the presence of enhancing levels of DENV immune sera (Budigi, et al., 2018).||Applications: |Suitable for use in ELISA and Western Blot. Other applications not tested.||Recommended Dilution:|Optimal dilutions to be determined by the researcher.||Storage and Stability:|May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.Product Type:Mab|Isotype: IgG2a,k|Host: Mouse|Concentration: ~1mg/ml|Form: Supplied as a liquid in PBS, pH 7.2, 0.05% sodium azide.|Purity: Purified by DEAE chromatography.|Specificity: Recognizes Dengue virus envelope protein. Reacts with envelope protein from Dengue Virus serotypes 1, 2, 3 and 4.||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

usbio的生化试剂，抗体，重组蛋白，细胞培养基和分子生物学试剂盒几乎用于所有科学应用和环境，包括基因组研究，生物技术，药物开发和疾病诊断。

恭喜苏州蚂蚁淘获得usbio2020年授权书，成为usbio中国代理，购买usbio,请认准usbio代理-苏州蚂蚁淘！